Business

Seven Indian pharma players race to develop vaccine for COVID-19

At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they join global efforts to find a preventive to check the spread of the deadly virus that has already infected more than 14 million globally.

migrator

New Delhi

Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India. Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within months because of the pandemic.

Bharat Biotech has received approval to conduct phase I and II clinical trial for its vaccine candidate Covaxin, that has been developed and manufactured in the company’s facility in Hyderabad. It last week started human clinical trials. Leading vaccine major Serum Institute of India has said that it is hoping to develop a COVID-19 vaccine by the year-end. Pharma major Zydus Cadila has said that it is looking to complete clinical trials of its COVID-19 vaccine candidate ZyCoV-D in seven months. Panacea Biotec in June said that it was setting up a joint venture firm in Ireland with US-based Refana Inc to develop a vaccine for COVID-19. Others like Mynvax and Biological E are also working to develop vaccines for COVID-19.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Cyclone Murasu: TN rushes 500 electricity dept personnel, equipment to AP to restore power

SC dismisses petition filed by former DMK minister Nehru in cash-for-job scam

DMK chief Stalin slams TVK govt over GST slump, loss of Rs 1,614 crore Korean investment to AP

CM Vijay inaugurates Rs 23 crore bus stand in Pudukottai

TASMAC retail outlets remain State-run as govt revises rules for private bars

SCROLL FOR NEXT